



(11) **EP 3 137 114 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 47/50 ^(2017.01) **C07K 16/26** ^(2006.01)
C07K 16/30 ^(2006.01) **C07K 16/40** ^(2006.01)
A61K 47/68 ^(2017.01) **A61P 35/00** ^(2006.01)
A61P 35/02 ^(2006.01)

(48) Corrigendum issued on:
04.08.2021 Bulletin 2021/31

(86) International application number:
PCT/US2015/027791

(45) Date of publication and mention
of the grant of the patent:
23.12.2020 Bulletin 2020/52

(87) International publication number:
WO 2015/168019 (05.11.2015 Gazette 2015/44)

(21) Application number: **15774735.3**

(22) Date of filing: **27.04.2015**

(54) **ANTI-PTK7 ANTIBODY-DRUG CONJUGATES**

ANTI-PTK7-ANTIKÖRPER-ARZNEIMITTELKONJUGATE

CONJUGUÉS MÉDICAMENT-ANTICORPS ANTI-PTK7

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **30.04.2014 US 201461986520 P**

(43) Date of publication of application:
08.03.2017 Bulletin 2017/10

(60) Divisional application:
20159103.9 / 3 711 780

(73) Proprietors:
• **Pfizer Inc.**
New York, NY 10017 (US)
• **AbbVie Stemcentrx LLC**
North Chicago, IL 60064 (US)

(72) Inventors:
• **DAMELIN, Marc Isaac**
Needham Heights
MA 02494-1506 (US)

• **SAPRA, Puja**
River Edge, New Jersey 07661 (US)
• **BANKOVICH, Alexander John**
San Francisco, California 94017 (US)
• **DYLLA, Scott J.**
Menlo Park
CA 94026 (US)

(74) Representative: **Wilding, James Roger et al**
Mathys & Squire
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
WO-A1-2012/112943 WO-A1-2012/162482
WO-A2-2007/067730 US-A1- 2013 122 020
US-A1- 2013 129 753

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).